Plain-English translation of NCT06983028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can safely help people with several types of autoimmune kidney diseases. These are conditions where the immune system attacks the kidneys, causing protein to leak into the urine and reducing kidney function. The study will give this medication as a weekly injection under the skin to see if it can slow or stop kidney damage better than current treatments alone.
Many people with these autoimmune kidney diseases continue to lose kidney function even when taking standard treatments, which can eventually lead to kidney failure. This trial is testing whether the medication can offer better protection for the kidneys and give patients additional hope beyond what existing therapies provide.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive weekly injections of the medication under your skin while continuing your current kidney disease treatments. You will attend regular clinic visits for blood tests, urine tests, and blood pressure checks so doctors can monitor how the medication is working and watch for side effects. The study will track how much protein is leaking into your urine and how well your kidneys are functioning over time to see if the new treatment helps.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Vera Therapeutics, Inc.
Enrollment target
~200 participants
Started
July 2025
Primary completion
November 2027
Age range
10 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vera Therapeutics, Inc. Clinical Trials Information
Vera Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.